Schrödinger's Bunsen Platform Named Drug Discovery Solution of the Year
Schrödinger's Bunsen platform was recognized as the 'Drug Discovery Solution of the Year' in the 2026 BioTech Breakthrough Awards.
Stocks · News reference
TD Cowen Maintains Buy on Schrodinger, Raises Price Target to $36
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Schrödinger Reports Q3 2026 Financial Results and Strategic Updates
Schrödinger, Inc. reported third-quarter 2026 revenue of $64.49 million, an 18.7% year-over-year increase, and announced an expanded collaboration with Novartis.
Schrödinger, Inc. Reports Third Quarter 2026 Financial Results
Schrödinger, Inc. announced its financial results for the third quarter ended September 30, 2026, reporting $64.5 million in revenue and raising its full-year outlook.
Schrödinger Says It Received Milestone Payment From Structure Therapeutics Tied To Phase 1/2a Study Of Obesity Candidate ACCG-2671
Schrodinger Q3 Adj. EPS $(0.50) Beats $(0.70) Estimate, Sales $64.491M Beat $47.258M Estimate
Schrödinger to Present at UBS Global Healthcare Conference
Schrödinger, Inc. announced that its management team will participate in a fireside chat at the upcoming UBS Global Healthcare Conference.